Articles by Daniel Marsh
Beyond Meat Plunges 20% as 1-for-30 Reverse Split Sets Up Nasdaq Deadline
Beyond Meat shares tumbled 19.7% to $0.4176 as the company's 1-for-30 reverse split takes effect, leaving only 12 sessions to meet Nasdaq's $1 minimum bid.
Joby Aviation Tumbles 4.4% on $500M Defense Buy, Cash Concerns
Joby Aviation (JOBY) dropped 4.43% after agreeing to buy Resonant Sciences for $500 million, with $450 million in cash, sparking investor worries about liquidity.
Bradesco Shares Slide as Capital Raise Prices Above Market
Bradesco's ADR dropped 3.6% after its capital raise priced above market. Q2 profit rose 16.2%, but the subscription price now sits 5.1% above the market.
ONDS Rises on Israeli Drone Deal, Yet Valuation Looms Large
Ondas shares gained 2.4% to $9.535 following an Israeli drone contract, but the stock's valuation at 10.35x 2026 revenue remains a concern. Q2 earnings are due Thursday.
Chipotle Shares Dip as Jalapeño Recall Tests Recovery
Chipotle (CMG) shares slipped 0.8% as the jalapeño recall from Taylor Farms heightens food safety concerns. FDA sees no active risk, but traffic recovery remains fragile.
Nokia Rebounds as AI Order Backlog Hits €2.8B, Analysts Stay Bullish
Nokia ADRs climbed 3.4% to $9.44 as investors weighed a massive €2.8B AI order backlog against a steep three-month decline. Analysts see upside, but conversion risks remain.
Jabil Stock Surges on UBS Buy Rating, AI Revenue Forecast
Jabil (JBL) shares jumped 3.3% after UBS upgraded the stock to Buy, projecting $20.3 billion in AI-related revenue for fiscal 2027.
Archer Aviation Surges on Boeing Unit Acquisition, Secures $200M Revenue Stream
Archer Aviation shares climbed 4.9% Tuesday after Boeing deal to acquire Wisk, Insitu, and SkyGrid, adding a $200M revenue stream and strategic assets.
Fermi Surges 16% on $6.5B TensorWave Lease, Financing Risks Loom
Fermi stock rose 16% after a $6.5B lease with TensorWave, but financing and construction risks persist. Shares remain far below IPO price.
AbCellera Surges 34% as Menopause Drug Hits Phase 2 Goals
AbCellera (ABCL) surged 34% after its menopause drug ABCL635 met Phase 2 efficacy endpoints, reducing hot flash frequency and severity with no dropouts.
Sionna Plunges 91% as CF Drug Fails Trial, Market Cap Drops Below Cash
Sionna shares fell 91% after its CF drug SION-719 failed a Phase 2a trial, with efficacy far below expectations. The stock now trades below cash value.